dc.contributor.author | Pisarska, Agnieszka | |
dc.contributor.author | Deluca, Paolo | |
dc.contributor.author | Demetrovics, Zsolt | |
dc.contributor.author | Corkery, John | |
dc.contributor.author | Moskalewicz, Jacek | |
dc.contributor.author | ReDNet Group | |
dc.contributor.author | Corazza, Ornella | |
dc.contributor.author | Corkery, John | |
dc.contributor.author | Stair, Jacqueline | |
dc.contributor.author | Fergus, Suzanne | |
dc.contributor.author | Pezzolesi, Cinzia | |
dc.contributor.author | Schifano, Fabrizio | |
dc.date.accessioned | 2020-03-22T01:20:42Z | |
dc.date.available | 2020-03-22T01:20:42Z | |
dc.date.issued | 2020-02-18 | |
dc.identifier.citation | Pisarska , A , Deluca , P , Demetrovics , Z , Corkery , J , Moskalewicz , J , ReDNet Group , , Corazza , O , Corkery , J , Stair , J , Fergus , S , Pezzolesi , C & Schifano , F 2020 , ' Novel psychoactive substances (NPS) – knowledge and experiences of drug users from Hungary, Poland, the UK and the USA ' , Neuropsychopharmacologia Hungarica , vol. 21 , no. 3 , pp. 152-163 . | |
dc.identifier.issn | 1419-8711 | |
dc.identifier.other | ORCID: /0000-0002-7134-0665/work/70885847 | |
dc.identifier.other | ORCID: /0000-0001-7371-319X/work/98163899 | |
dc.identifier.uri | http://hdl.handle.net/2299/22450 | |
dc.description | Funding Information: This publication arises from the activities of the RedNet Research Project which have received funding from the EU in the framework of the Public Health Programme (2009 12 16). Zsolt Demetrovics acknowledges the support of the Hungarian National Research, Development and Innovation Office (Grant numbers: K111938, KKP126835). Funding Information: Acknowledgment: This publication arises from the activities of the RedNet Research Project which have received funding from the EU in the framework of the Public Health Programme (2009 12 16). Zsolt Demetrovics acknowledges the support of the Hungarian National Research, Development and Innovation Office (Grant numbers: K111938, KKP126835). Publisher Copyright: © 2019, Hungarian Association of Psychopharmacology. All rights reserved. | |
dc.description.abstract | Dopamine D 3 receptor partial agonists represent a new generation of atypical antipsychotics. Cariprazine, which has received centralized market authorization from the European Medicines Agency in 2017 for the treatment of adult patients with schizophrenia (including those with predominant negative symptoms of schizophrenia) differs from the other two partial agonist antipsychotics aripiprazole and brexpiprazole due to its unique features. Cariprazine is a dopamine D 3 preferring D 3/D2 partial agonist with very similar dopamine receptor sub-type selectivity as dopamine. It has proven efficacy in the treatment of positive and negative symptoms of schizophrenia, as well as for relapse prevention. Further phase-3 clinical studies proved the efficacy of cariprazine in the acute treatment of manic or mixed episodes associated with bipolar I disorder, as well as in bipolar depression. For the adjunctive treatment of major depressive disorder, phase 3 studies are in progress. | en |
dc.format.extent | 11 | |
dc.format.extent | 146428 | |
dc.language.iso | eng | |
dc.relation.ispartof | Neuropsychopharmacologia Hungarica | |
dc.subject | novel psychoactive substances | |
dc.subject | drugs | |
dc.subject | addiction | |
dc.subject | delegalisation | |
dc.subject | international study | |
dc.subject | Predominant negative symptoms | |
dc.subject | Atypical antipsychotic | |
dc.subject | Cariprazine | |
dc.subject | Schizophrenia | |
dc.subject | Dopamine D and D receptor partial agonist | |
dc.subject | Clinical Neurology | |
dc.subject | Neuropsychology and Physiological Psychology | |
dc.subject | General Neuroscience | |
dc.subject | Pharmacology, Toxicology and Pharmaceutics(all) | |
dc.title | Novel psychoactive substances (NPS) – knowledge and experiences of drug users from Hungary, Poland, the UK and the USA | en |
dc.contributor.institution | Centre for Clinical Practice, Safe Medicines and Drug Misuse Research | |
dc.contributor.institution | Centre for Health Services and Clinical Research | |
dc.contributor.institution | Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Unit | |
dc.contributor.institution | School of Life and Medical Sciences | |
dc.contributor.institution | Department of Clinical, Pharmaceutical and Biological Science | |
dc.contributor.institution | Centre for Future Societies Research | |
dc.contributor.institution | Centre for Hazard Detection and Protection Research | |
dc.contributor.institution | Centre for Research in Mechanisms of Disease and Drug Discovery | |
dc.contributor.institution | Nanopharmaceutics | |
dc.contributor.institution | Natural Product Chemistry and Drug Design | |
dc.description.status | Peer reviewed | |
dc.identifier.url | https://pubmed.ncbi.nlm.nih.gov/32015192/ | |
rioxxterms.type | Journal Article/Review | |
herts.preservation.rarelyaccessed | true | |